Supplementary Appendix

Size: px
Start display at page:

Download "Supplementary Appendix"

Transcription

1 Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI trial) Marcus Lind, MD, PhD, Associate Professor 1,2, Irl B Hirsch, MD, Professor 3, Jaakko Tuomilehto, MD, Professor 4, Sofia Dahlqvist 2, Bo Ahrén, MD, Professor 5, Ole Torffvit, MD, PhD, Associate Professor 5, Stig Attvall, MD, PhD, Associte Professor 1, Magnus Ekelund, MD, PhD 5, Karin Filipsson, MD, PhD 5, Bengt-Olov Tengmark, MD, PhD, Associate Professor 6, Stefan Sjöberg, MD, PhD, Associate Professor 7, Nils-Gunnar Pehrsson, BA 8 1. Institute of Medicine, University of Gothenburg, Gothenburg, Sweden 2. Department of Medicine, NU-Hospital Group, Uddevalla, Sweden 3. University of Washington, Seattle, U.S. 4. Centre for Vascular Prevention, Danube-University, Krems, Austria; Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland; Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia 5. Lund University, Lund, Sweden 6. Citydiabetes, Stockholm 7. Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Medicine, Halland County Hospital, Halmstad Sweden 8. Statistiska Konsultgruppen, Gothenburg, Sweden 1

2 1 Table of contents 1 Table of contents Procedure for randomisation Changes to eligibility criteria Tables etable 1. Protocol deviations leading to exclusion from Per Protocol population etable 2. Efficacy analyses of the Per Protocol population etable 3. Efficacy analyses of predefined endpoints of all randomised patients

3 2 Procedure for randomisation Treatment kits labelled with sequential code, with the content of each code determined and packed from a traditional block randomisation scheme were used. For label codes, block randomisation was performed with blocks 2+2. The block randomisation scheme for labelling and packaging was created by a statistician, and forwarded to the National Pharmacy, Sweden for packaging/labelling and to one (1) dedicated unblinded data manager for setting up the computerized system that applies the minimization algorithm for label code assignment to subjects. Label codes were assigned to subjects using a central computerized system that applies a minimization algorithm to ensure good statistical balance arms. The system is aware of the treatment arm behind each label code and the available supply at each site, and internally randomises to a treatment arm and then selects, randomly, and reveals a label code matching the treatment arm. Minimization was balancing on the following variables age, sex, weight, HbA1c, and total daily insulin dose, and applies an in- treatment arms difference of max 4 at study level and max 2 at site level. Statistiska Konsultgruppen performed the randomisation scheme. Sites enrolled participants and assigned the intervention, using the above described computerized system. The statistician who created the block randomisation scheme, the National Pharmacy, and one data manager were unblinded. All study personnel and participants were blinded to treatment. The blind was broken by the data manager after clean file and database lock. 3 Changes to eligibility criteria The inclusion/exclusion criteria were changed partly to use more general and conventional cut-offs for variables and partly to facilitate further recruitment. The following changes were made: Lower limit of HbA1c was changed from 8.0% to 7.8% (64 to 62 mmol/l) on 28 January 2013, and from 7.8% to 7.5% (62 to 58 mmol/l) on 2 April Lower limit of C-peptide was changed from 0.2 to 0.15 on 28 January 2013 and from 0.15 to 0.10 nmol/l on 11 July Upper limit of calcitonin was changed from 50 ng/l to 14.6 pmol/l on 28 January Lower limit of fasting glucose was changed from 7.0 to 6.0 mmol/l on 28 January Accepted contraceptive methods were defined from e.g. oral contraceptive pills and intrauterine device (IUD) to accepted methods: oral contraceptive pills, depo provera contraceptive injections, implanted contraceptive, transdermal patch, intrauterine device, vasectomized partner, or abstinence. on 28 January Lower limit of BMI was changed from 28 to 27.5 kg/m 2 on 30 January Upper age limit was changed from 75 to 80 years on 17 June Upper limit of creatinine was changed from 130 to 150 micromol/l on 20 June 2013 Exclusion due to systemic glucocorticoid treatment was changed so that individual treated with systemic corticoid treatment for substitution of cortisol deficiency were able to participate. Changed on 28 August

4 4 Tables 4.1 etable 1. Protocol deviations leading to exclusion from Per Protocol population Variable (n=64) (n=60) Non-PP 6 (9.4%) 5 (8.3%) Reason for exclusion specified Baseline HbA1c sampled long before Baseline visit 2 (33.3%) 2 (40.0%) Early Termination 2 (33.3%) 0 (0.0%) Early Termination + early rescue therapy 0 (0.0%) 1 (20.0%) Early rescue therapy, before 6W 0 (0.0%) 1 (20.0%) Early rescue therapy, W12 and W18 0 (0.0%) 1 (20.0%) Incorrectly included, with too low c-peptide 1 (16.7%) 0 (0.0%) Periods of not taking study medication, including the time before 18W & 24W visits For categorical variables n (%) is presented. 1 (16.7%) 0 (0.0%) 4

5 4.2 etable 2. Efficacy analyses of the Per Protocol population Variable HbA1c (IFCC; mmol/mol), from Baseline to 24 W (10.0) -18 (-46; 11) HbA1c (NGSP; %), from Baseline to 24W (0.92) (-4.21; 1.01) (n=58) (-19.3 to -14.2) (-1.76 to -1.30) (9.88) -3 (-26; 23) (0.904) (-2.379; 2.105) (n=55) p-value (-6.94 to -1.76) (-0.64 to -0.16) Means <.0001 < (-16.0 to - 8.8) <.0001 < (-1.47 to ) Weight (kg), from Baseline to 24W (3.11) (-12.6; 2.1) Fasting Plasma Glucose (mmol/l), from Baseline to 24W (3.39) -1.4 (-14.7; 4.0) HbA1c less than 8.0% (64 mmol/mol) at 24W (-4.55 to -3.04) (-2.41 to -1.16) (2.65) -0.1 (-12.6; 6.1) (2.812) 0.0 (-9.8; 5.2) >= 8.0% (64 mmol/mol) 14 (24.1%) 32 (58.2%) ( to 0.748) ( to 0.156) < 8.0% (64 mmol/mol) 44 (75.9%) 23 (41.8%) HbA1c less than 7.5% (58 mmol/mol) at 24W <.0001 < (-4.85 to ) (-2.20 to ) 5

6 (n=58) >= 7.5% (58 mmol/mol) 23 (39.7%) 42 (76.4%) (n=55) p-value < 7.5% (58 mmol/mol) 35 (60.3%) 13 (23.6%) HbA1c less than 7.0% (53 mmol/mol) at 24W >= 7.0% (53 mmol/mol) 32 (55.2%) 52 (94.5%) < 7.0% (53 mmol/mol) 26 (44.8%) 3 (5.5%) <.0001 Total daily Meal and Basal insulin (Units), from Baseline to 24W (24.0) -12 (-92; 22) CGM Mean (mmol/l), from Baseline to 24W (2.12) (-6.77; 3.84) n=57 CGM SD (mmol/l), from Baseline to 24W (0.718) (-1.767; 1.936) n=57 Number of symptomatic non-severe hypoglycemia < (2.58) 0 (0; 16) (-23.8 to -13.2) (-2.31 to -1.27) ( to ) (18.88) 0 (-89; 27) (2.081) (-3.715; 5.628) n= (0.696) (-1.274; 1.874) n= (3.57) 0 (0; 19) (-8.84 to 2.09) ( to 0.632) ( to 0.211) Means (-22.8 to - 7.5) <.0001 < (-2.63 to ) <.0001 < ( to )

7 Number of asymptomatic non-severe hypoglycemia < (0.539) 0 (0; 4) (n=58) (0.229) 0 (0; 1) (n=55) p-value 0.94 Means Number of symptomatic non-severe hypoglycemia < (0.954) 0 (0; 4) (0.990) 0 (0; 5) 0.57 Number of asymptomatic non-severe hypoglycemia < (0.00) 0.00 (0.00) 1.00 Number of Severe hypoglycemia, Baseline to 24W 0.00 (0.00) 0.00 (0.00) 1.00 Treatment Satisfaction Status Scale Total, from Baseline to 24W Treatment Satisfaction Change Scale Total (range -18 to 18), at 24W 5.16 (7.02) 3 (-7; 28) n= (4.6) 15 (-2; 18) n= (3.19 to 6.31) 1.11 (7.95) 1 (-23; 19) n= (6.84) 11 (-7; 18) n= (-0.05 to 3.11) (1.00 to 5.45)

8 Mean Postprandial glucose level (mmol/l), from Baseline to 24W (2.90) (-13.55; 4.15) n=50 Fasting total cholesterol (mmol/l), from Baseline to 24W (0.541) -0.1 (-1.3; 1.6) n=57 Fasting High-Density Lipoprotein (HDL) cholesterol (mmol/l), from Baseline to 24W Fasting Low-Density Lipoprotein (LDL) cholesterol (mmol/l), from Baseline to 24W (0.137) 0.0 (-0.3; 0.4) n=57 (n=58) (0.497) (-1.1; 1.6) n=56 Fasting Triglycerides (mmol/l), from Baseline to 24W (1.005) (-2.86; 3.40) n= (-3.06 to -1.46) ( to 0.086) (0.003 to 0.075) ( to 0.001) ( to 0.938) (3.229) (-7.000; 6.033) n= (0.718) 0.0 (-2.5; 2.9) n= (0.140) 0.0 (-0.3; 0.4) n= (0.487) -0.1 (-2.1; 1.2) n= (4.030) 0.10 (-2.60; 28.80) n=53 (n=55) p-value ( to 0.604) ( to 0.187) ( to 0.059) ( to 0.033) ( to 1.186) Means (-3.19 to ) ( to 0.134) ( to 0.070) ( to 0.160) 0.72 (0.72;0. 73)* ( to 0.855) 8

9 Systolic Blood Pressure (mmhg), from Baseline to 24W (12.98) -4 (-38; 24) n=56 Diastolic Blood Pressure (mmhg), from Baseline to 24W (10.489) 1 (-20; 26) n=56 For categorical variables n (%) is presented. For continuous variables / / n= is presented. For comparison Fisher s Exact test was used for dichotomous variables and the Fisher s Non Parametric Permutation Test was used for continuous variables. *) Adjustment for variable baseline values is made using Analysis of Covariance (ANCOVA). (n=58) (-7.22 to -0.93) ( to 2.602) 1.91 (13.11) 3.5 (-47; 28) n= (10.741) -0.5 (-27; 43) n=54 (n=55) p-value ( to 4.135) ( to 2.562) Means (-9.53 to ) ( to 3.519) 9

10 4.3 etable 3. Efficacy analyses of predefined endpoints of all randomised patients. Variable HbA1c (IFCC; mmol/mol), from Baseline to 24W (10.48) -18 (-46; 11) HbA1c (NGSP; %), from Baseline to 24W (0.96) (-4.21; 1.01) (n=64) Weight (kg), from Baseline to 24W (3.11) -3.5 (-12.6; 2.1) Fasting Plasma Glucose (mmol/l), from Baseline to 24W (3.39) -1.4 (-14.7; 4.0) ( to ) (-1.74 to ) (-4.43 to ) (-2.37 to ) (n=60) (9.66) -3.5 (-26; 23) (0.88) (-2.38; 2.10) 0.06 (2.72) 0.0 (-12.6; 6.1) (2.96) 0.1 (-9.8; 7.9) (-7.03 to ) (-0.64 to ) (-0.70 to ) (-0.89 to 0.39) p- value Adjuste d Means <.0001 < (-15.6 to - 8.6) <.0001 < (-1.42 to ) <.0001 < (-4.80 to ) (-2.39 to ) 10

11 HbA1c less than 64 mmol/mol (8.0%) at 24W (n=64) (n=60) >= 64 mmol/mol (8.0%) 17 (26.6%) 37 (61.7%) < 64 mmol/mol (8.0%) 47 (73.4%) 23 (38.3%) HbA1c less than 58 mmol/mol (7.5%) at 24W >= 58 mmol/mol (7.5%) 27 (42.2%) 47 (78.3%) < 58 mmol/mol (7.5%) 37 (57.8%) 13 (21.7%) <.0001 HbA1c less than 53 mmol/mol (7.0%) at 24W >= 53 mmol/mol (7.0%) 37 (57.8%) 57 (95.0%) < 53 mmol/mol (7.0%) 27 (42.2%) 3 (5.0%) <.0001 Total daily Meal and Basal insulin (Units), from Baseline to 24W (23.37) -12 (-92; 22) CGM Mean (mmol/l), from Baseline to 24W (2.24) (-7.86; 3.84) n= ( to ) (-2.24 to ) (19.05) 0 (-89; 41) 0.17 (2.03) (-3.71; 5.63) n= (-7.45 to 2.90) (-0.41 to 0.66) p- value Adjuste d Means <.0001 < (-22.7 to - 8.3) <.0001 < (-2.59 to ) 11

12 CGM SD (mmol/l), from Baseline to 24W (0.74) (-1.77; 1.94) n=63 Number of symptomatic non-severe hypoglycaemia < (2.48) 0 (0; 16) (n=64) (-0.62 to ) (n=60) 0.04 (0.67) 0.04 (-1.27; 1.87) n= (3.44) 0 (0; 19) (-0.14 to 0.22) p- value Adjuste d Means (-0.73 to ) 0.96 Number of asymptomatic non-severe hypoglycaemia < 4.0 Number of symptomatic non-severe hypoglycaemia < (0.51) 0 (0; 4) 0.36 (0.91) 0 (0; 4) 0.05 (0.22) 0 (0; 1) 0.25 (0.95) 0 (0; 5) 0.94 (0.94;0. 94)** 0.59 Number of asymptomatic non-severe hypoglycaemia < (0.00) 0.00 (0.00) 1.00 Number of Severe hypoglycaemia, Baseline to 24W 0.00 (0.00) 0.00 (0.00)

13 Treatment Satisfaction Status Scale Total, from Baseline to 24W 4.62 (6.80) 2 (-7; 28) n=63 Treatment Satisfaction Change Scale Total (range -18 to 18), at 24W (4.48) 15.5 (-2; 18) n=58 Mean Postprandial glucose level (mmol/l), from Baseline to 24W (2.85) (-13.55; 4.15) n=53 (n=64) Fasting total cholesterol (mmol/l), from Baseline to 24W (0.54) -0.1 (-1.3; 1.6) Fasting High-Density Lipoprotein (HDL) cholesterol (mmol/l), from Baseline to 24W 0.04 (0.15) 0.0 (-0.3; 0.5) (2.71 to 5.74) (-2.98 to ) (-0.23 to 0.08) (0.01 to 0.08) (n=60) 0.97 (7.96) 1 (-23; 19) n= (6.76) 11 (-7; 18) n= (3.21) (-7.00; 6.03) n= (0.72) 0.0 (-2.5; 2.9) n= (0.14) 0.0 (-0.3; 0.4) n= (-0.18 to 2.95) (-1.00 to 0.62) (-0.11 to 0.21) (-0.01 to 0.06) p- value Adjuste d Means (0.66 to 5.03) (-3.14 to ) (-0.34 to 0.10) ( to 0.065) 13

14 Fasting Low-Density Lipoprotein (LDL) cholesterol (mmol/l), from Baseline to 24W (n=64) (0.50) -0.1 (-1.1; 1.6) n=62 Fasting Triglycerides (mmol/l), from Baseline to 24W 0.05 (0.97) (-2.86; 3.40) Systolic Blood Pressure (mmhg), from Baseline to 24W (13.11) -4 (-38; 24) Diastolic Blood Pressure (mmhg), from Baseline to 24W 0.67 (10.09) 1 (-20; 26) (-0.24 to 0.00) (-0.56 to 0.77) (-7.60 to ) (-1.92 to 2.57) (n=60) (0.52) -0.1 (-2.1; 1.4) n= (3.82) 0.00 (-2.60; 28.80) n= (13.09) 2.5 (-47; 28) 0.22 (10.49) 0 (-27; 43) (-0.19 to 0.07) (-0.29 to 1.10) (-1.85 to 4.14) (-1.73 to 2.90) p- value Adjuste d Means (-0.24 to 0.12) 0.66 (0.66;0. 66)** (-1.26 to 0.67) ( to ) (-3.49 to 2.97) 14

15 (n=64) (n=60) p- value Adjuste d Means For categorical variables n (%) is presented. For continuous variables / / n= is presented. For comparison Fisher s Exact test was used for dichotomous variables and the Fisher s Non Parametric Permutation Test was used for continuous variables. *) Adjustment for variable baseline values is made using Analysis of Covariance (ANCOVA). **) The Fisher Non Parametric Permutation Test failed to approximate the p-value so Monte Carlo simulation (p-value (99% CI)) of Fisher Non Parametric Permutation Test was used instead. 15

Statistical Analysis Plan FINAL. DexComG4 (DexCom Corporation) CGMMDI GOLD-Study

Statistical Analysis Plan FINAL. DexComG4 (DexCom Corporation) CGMMDI GOLD-Study 1.0 Page 1 of 15 FINAL DexComG4 (DexCom Corporation) CGMMDI GOLD-Study monitoring (CGM) in individuals with type 1 diabetes treated 2016-07-07 Approvals Name/Title: Nils-Gunnar Pehrsson / Statistiska Konsultgruppen,

More information

Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)

Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial) open access Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial) Marcus Lind, 1,2 Irl B Hirsch, 3 Jaakko Tuomilehto,

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia

More information

23-Aug-2011 Lixisenatide (AVE0010) - EFC6014 Version number: 1 (electronic 1.0)

23-Aug-2011 Lixisenatide (AVE0010) - EFC6014 Version number: 1 (electronic 1.0) SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of metformin

More information

Supplementary Table 1. Patient demographics and baseline characteristics (treated patients).

Supplementary Table 1. Patient demographics and baseline characteristics (treated patients). Supplementary Table 1. Patient demographics and baseline characteristics (treated patients). Placebo (n=188) 10 mg (n=186) 25 mg (n=189) Total (n=563) Gender, n (%) Male 75 (40) 97 (52) 84 (44) 256 (45)

More information

Efficacy/pharmacodynamics: 85 Safety: 89

Efficacy/pharmacodynamics: 85 Safety: 89 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: Sanofi Drug substance:

More information

SYNOPSIS. Administration: subcutaneous injection Batch number(s):

SYNOPSIS. Administration: subcutaneous injection Batch number(s): SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top

More information

SCIENTIFIC STUDY REPORT

SCIENTIFIC STUDY REPORT PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Lingvay I, Manghi FP, García-Hernández P, et al. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with type

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

egfr > 50 (n = 13,916)

egfr > 50 (n = 13,916) Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according

More information

SYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)

SYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only) SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI. PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery

More information

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

These results are supplied for informational purposes only.

These results are supplied for informational purposes only. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information

Investigators, study sites Multicenter, 35 US sites. Coordinating Investigator: Richard Bergenstal, MD

Investigators, study sites Multicenter, 35 US sites. Coordinating Investigator: Richard Bergenstal, MD STUDY SYNOPSIS Study number Title HMR1964A/3502 Apidra (insulin glulisine) administered in a fixed-bolus regimen vs. variable-bolus regimen based on carbohydrate counting in adult subjects with type 2

More information

Study Code: Date: 27 July 2007

Study Code: Date: 27 July 2007 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:

More information

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values

More information

Supplementary Data. Formula S1. Calculation of IG fluctuation from continuous glucose monitoring profiles Z T 1 T

Supplementary Data. Formula S1. Calculation of IG fluctuation from continuous glucose monitoring profiles Z T 1 T Supplementary Data Formula S1. Calculation of IG fluctuation from continuous glucose monitoring profiles 1 T Z T O jig(t) IGjdt IG, interstitial glucose; IG(t), IG value at time t; IG, mean IG from the

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Lind M, Polonsky W, Hirsch IB, et al. Effect of continuous glucose monitoring vs conventional therapy on glycemic control among patients type 1 diabetes treated multiple daily

More information

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Sponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

Sponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

JARDIAMET. (empagliflozin and metformin hydrochloride) 5 mg/500 mg, 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/500 mg, 12.5 mg/850 mg, 12.

JARDIAMET. (empagliflozin and metformin hydrochloride) 5 mg/500 mg, 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/500 mg, 12.5 mg/850 mg, 12. JARDIAMET (empagliflozin and metformin hydrochloride) 5 mg/500 mg, 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/500 mg, 12.5 mg/850 mg, 12.5 mg/1000 mg NAME OF THE MEDICINE JARDIAMET contains two oral antihyperglycaemic

More information

Non-insulin treatment in Type 1 DM Sang Yong Kim

Non-insulin treatment in Type 1 DM Sang Yong Kim Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay

More information

Deprivation Study. The Freiburg Study

Deprivation Study. The Freiburg Study The Freiburg Study Deprivation Study Free Radicals Inflammation (hs-crp) Blood Pressure (Systolic, Diastolic) Blood Lipids (Cholesterol, Triglycerides) Energy Utilization (Heart Rate) Sugar Metabolism

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and weight change with cardiovascular disease among people with and without diabetes. JAMA. doi:10.1001/jama.2013.1644.

More information

SUPPLEMENTARY DATA. Supplementary Methods

SUPPLEMENTARY DATA. Supplementary Methods Supplementary Methods Chronic kidney disease stage 4 or 5 Current diabetic foot with ulcer, soft tissue infection or necrosis Unstable angina, myocardial infarction, or cerebrovascular accident over the

More information

Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial

Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial Dr Sandra Neoh on behalf of: Dr Denice Feig and Professor Helen Murphy Funders: JDRF (Juvenile Diabetes Research Foundation),

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures Supplementary Data Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures Quintiles of Systolic Blood Pressure Quintiles of Diastolic Blood Pressure Q1 Q2

More information

SYNOPSIS. Abbreviated Clinical Study Report. Study Code: RIMON_L_01031 Document Status: Synopsis V 2.1 Date: 16-Oct Title of the study:

SYNOPSIS. Abbreviated Clinical Study Report. Study Code: RIMON_L_01031 Document Status: Synopsis V 2.1 Date: 16-Oct Title of the study: SYNOPSIS Title of the study: Investigator(s): A 12-month multicentre, randomised, double-blind, placebo-controlled study with two parallel groups to assess the effects of rimonabant 20 mg in patients with

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. Published online November 7, 2016.

More information

4. resisted training ** OR resistance training * OR resisted exercise ** OR resistance exercise ** OR strength training ** OR strength exercise **

4. resisted training ** OR resistance training * OR resisted exercise ** OR resistance exercise ** OR strength training ** OR strength exercise ** Supplementary Table 1. Search strategy (up to January 10 th 2015). MEDLINE Result: 253 studies 1. clinical trial ** OR controlled trial ** OR randomized controlled trial * OR randomised controlled trial

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Sigal RJ, Alberga AS, Goldfield GS, et al. Effects of aerobic training, resistance training, or both on percentage body fat and cardiometabolic risk markers in obese adolescents:

More information

iglarlixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L

iglarlixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L Diabetes Ther (2018) 9:373 382 https://doi.org/10.1007/s13300-017-0336-6 BRIEF REPORT iglarlixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post

More information

Glycemic Control, Renal Complications, and Current Smoking in Relation to Excess Risk of Mortality in Persons With Type 1 Diabetes

Glycemic Control, Renal Complications, and Current Smoking in Relation to Excess Risk of Mortality in Persons With Type 1 Diabetes 652901DSTXXX10.1177/1932296816652901Journal of Diabetes Science and TechnologyAhlén et al research-article2016 Special Section Glycemic Control, Renal Complications, and Current Smoking in Relation to

More information

Sponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes

Sponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309

More information

Clinical Trial Synopsis TL-OPI-518, NCT#

Clinical Trial Synopsis TL-OPI-518, NCT# Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride

More information

SYNOPSIS OF RESEARCH REPORT (PROTOCOL BC20779)

SYNOPSIS OF RESEARCH REPORT (PROTOCOL BC20779) TITLE OF THE STUDY / REPORT No. / DATE OF REPORT INVESTIGATORS / CENTERS AND COUNTRIES Clinical Study Report Protocol BC20779: Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Afkarian M, Zelnick L, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. doi:10.1001/jama.2016.10924 emethods efigure

More information

Online Appendices Online Appendix 1 Online Appendix 2 Online Appendix 3a Online Appendix 3b Online Appendix 3c Online Appendix 4 Online Appendix 5

Online Appendices Online Appendix 1 Online Appendix 2 Online Appendix 3a Online Appendix 3b Online Appendix 3c Online Appendix 4 Online Appendix 5 Online Appendices Online Appendix 1 Search terms used to identify studies Online Appendix 2 The identification process for eligible studies Online Appendix 3a- Niacin, Risk of bias table Online Appendix

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Anagnostou E, Aman MG, Handen BL, et al. Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autistic spectrum disorder:

More information

Statistical Analysis Plan

Statistical Analysis Plan Statistical Analysis Plan A randomised controlled trial evaluation of the effectiveness of three minimal human contact interventions to promote fitness and physical activity in an occupational health setting.

More information

Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms

Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Men (%) 20 (55) 54 (67) 0.216 Age (years) 57 ± 10 56 ±

More information

SUPPLEMENTARY DATA. Supplementary Figure 1. PubMed

SUPPLEMENTARY DATA. Supplementary Figure 1. PubMed Supplementary Figure 1. PubMed ((((((type 2 diabetes[title/abstract] OR type II diabetes[title/abstract] OR non-insulin diabetes[title/abstract]) AND (monounsaturated[title/abstract] OR polyunsaturated[title/abstract]

More information

programme. The DE-PLAN follow up.

programme. The DE-PLAN follow up. What are the long term results and determinants of outcomes in primary health care diabetes prevention programme. The DE-PLAN follow up. Aleksandra Gilis-Januszewska, Noël C Barengo, Jaana Lindström, Ewa

More information

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine. Study Identifiers: NCT

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine. Study Identifiers: NCT These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

NHS BLOOD AND TRANSPLANT ORGAN DONATION AND TRANSPLANTATION DIRECTORATE PANCREAS ADVISORY GROUP AUDIT OF STANDARD CRITERIA FOR LISTING SUMMARY

NHS BLOOD AND TRANSPLANT ORGAN DONATION AND TRANSPLANTATION DIRECTORATE PANCREAS ADVISORY GROUP AUDIT OF STANDARD CRITERIA FOR LISTING SUMMARY INTRODUCTION NHS BLOOD AND TRANSPLANT ORGAN DONATION AND TRANSPLANTATION DIRECTORATE PANCREAS ADVISORY GROUP AUDIT OF STANDARD CRITERIA FOR LISTING SUMMARY 1 Selection criteria for patients onto the national

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid

More information

SITA 100 mg (n = 378)

SITA 100 mg (n = 378) Supplementary Table 1. Summary of Sulfonylurea Background Therapy at Baseline and During the Treatment Period. Sulfonylurea at baseline, n (%) SITA 100 mg (n = 378) CANA 300 mg (n = 377) Total (N = 755)

More information

Table S2: Anthropometric, clinical, cardiovascular and appetite outcome changes over 8 weeks (baseline-week 8) by snack group

Table S2: Anthropometric, clinical, cardiovascular and appetite outcome changes over 8 weeks (baseline-week 8) by snack group Table S1: Nutrient composition of cracker and almond snacks Cracker* Almond** Weight, g 77.5 g (5 sheets) 56.7 g (2 oz.) Energy, kcal 338 364 Carbohydrate, g (kcal) 62.5 12.6 Dietary fiber, g 2.5 8.1 Protein,

More information

Facilitating EndotracheaL Intubation by Laryngoscopy technique and Apneic Oxygenation Within the Intensive Care Unit (FELLOW)

Facilitating EndotracheaL Intubation by Laryngoscopy technique and Apneic Oxygenation Within the Intensive Care Unit (FELLOW) Facilitating EndotracheaL Intubation by Laryngoscopy technique and Apneic Oxygenation Within the Intensive Data Analysis Plan: Apneic Oxygenation vs. No Apneic Oxygenation Background Critically ill patients

More information

Supplementary Online Content. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and

Supplementary Online Content. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and 1 Supplementary Online Content 2 3 4 5 6 Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on sympton burden and severity in patients with atrial

More information

DMEP Study Section 1 1

DMEP Study Section 1 1 DMEP Study Section 1 1 1. EXECUTIVE SUMMARY 1.1 Objectives The specific aims of the Diabetes Mellitus Education Program (DMEP) were to examine the role of the community pharmacist in the disease state

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Engebretson SP, Hyman LG, Michalowicz BS, et al. The effect of nonsurgical periodontal therapy on hemoglobin A1c levels among persons with type 2 diabetes and chronic periodontitis:

More information

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD

More information

These results are supplied for informational purposes only.

These results are supplied for informational purposes only. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content McEvoy JW, Chen Y, Ndumele CE, et al. Six-year change in high-sensitivity cardiac troponin T and risk of subsequent coronary heart disease, heart failure, and death. JAMA Cardiol.

More information

(a) y = 1.0x + 0.0; r = ; N = 60 (b) y = 1.0x + 0.0; r = ; N = Lot 1, Li-heparin whole blood, HbA1c (%)

(a) y = 1.0x + 0.0; r = ; N = 60 (b) y = 1.0x + 0.0; r = ; N = Lot 1, Li-heparin whole blood, HbA1c (%) cobas b system - performance evaluation Study report from a multicenter evaluation of the new cobas b system for the measurement of HbAc and lipid panel Introduction The new cobas b system provides a point-of-care

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Xu X, Qin X, Li Y, et al. Efficacy of folic acid therapy on the progression of chronic kidney disease: the Renal Substudy of the China Stroke Primary Prevention Trial. JAMA

More information

What is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming

What is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming The Bionic Pancreas Is Coming Montana Diabetes Professional Conference October 23, 2014 H. Peter Chase, MD Professor of Pediatrics University of Colorado Barbara Davis Center Stanford: Bruce Buckingham,

More information

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution of A: total cholesterol (TC); B: low-density lipoprotein

More information

Sponsor Novartis. Generic Drug Name. Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title

Sponsor Novartis. Generic Drug Name. Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title Sponsor Novartis Generic Drug Name Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title A randomized, double-blind, multi-center, active-controlled, parallel

More information

Author Correction to: Diabetes Ther https://doi.org/ /s

Author Correction to: Diabetes Ther https://doi.org/ /s Diabetes Ther (2018) 9:613 621 https://doi.org/10.1007/s13300-018-0386-4 AUTHOR CORRECTIO Author Correction: Effectiveness and Safety of a ovel Care Model for the Management of Type 2 Diabetes at 1 Year:

More information

Continuous intraperitoneal insulin infusion in the treatment of type 1 diabetes mellitus van Dijk, P.R.

Continuous intraperitoneal insulin infusion in the treatment of type 1 diabetes mellitus van Dijk, P.R. University of Groningen Continuous intraperitoneal insulin infusion in the treatment of type 1 diabetes mellitus van Dijk, P.R. IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's

More information

Number of patients: Planned: 403 Randomized: 391 Treated: 390 Efficacy: 363 (Full analysis set) 356 (Per-protocol set)

Number of patients: Planned: 403 Randomized: 391 Treated: 390 Efficacy: 363 (Full analysis set) 356 (Per-protocol set) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company : sanofi-aventis

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response

More information

THE SHEFFIELD AREA PRESCRIBING GROUP. Position Statement for Prescribing of Freestyle Libre In Type 1 Diabetes. Date: March 2018.

THE SHEFFIELD AREA PRESCRIBING GROUP. Position Statement for Prescribing of Freestyle Libre In Type 1 Diabetes. Date: March 2018. THE SHEFFIELD AREA PRESCRIBING GROUP Position Statement for Prescribing of Freestyle Libre In Type 1 Diabetes Date: March 2018 Overview Freestyle Libre is a flash glucose sensor device that measures *interstitial

More information

hypoglycaemia unawareness keystone 18 July 2014

hypoglycaemia unawareness keystone 18 July 2014 hypoglycaemia unawareness keystone 18 July 2014 Hypoglycaemia unawareness: ( Impaired awareness of hypoglycaemia ) Philip Home Newcastle University Philip Home Duality of interest Manufacturers of glucose-lowering

More information

RCHC Clinical Guidelines Type 2 Diabetes; Adults

RCHC Clinical Guidelines Type 2 Diabetes; Adults RCHC Clinical Guidelines Type 2 Diabetes; Adults Screening for diabetes in asymptomatic adults 1 Population: Aged > 45 years; Aged < 45 years who are overweight (BMI> 25kg/m 2 ) and have an additional

More information

PLEASE REMEMBER TO BRING TO EACH APPOINTMENT

PLEASE REMEMBER TO BRING TO EACH APPOINTMENT PLEASE REMEMBER TO BRING TO EACH APPOINTMENT Conversion table for HbA1c% to mmol/mol Old DCCT aligned HbA1c(%) New IFCC HbA1c (mmol/mol) 4.0 20 5.0 31 6.0 42 6.5 48 7.0 53 7.5 59 8.0 64 9.0 75 10.0 86

More information

Cohort 2. Age, years 41.0 (10.2) Diabetes duration, years 26.5 (15.8)

Cohort 2. Age, years 41.0 (10.2) Diabetes duration, years 26.5 (15.8) Supplementary Table. Participant characteristics in cohort Cohort Number Sex, Male Female Age, years. (.) Diabetes duration, years.5 (5.) BMI, kg.m. (3.) HbA c, % mmol.mol. (.7) () C-peptide, nmol.l.3

More information

Sponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

Sponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

Synopsis. Abstracts submitted to the EASD 2006 and IDF 2006 conferences. 7 June May Phase 4

Synopsis. Abstracts submitted to the EASD 2006 and IDF 2006 conferences. 7 June May Phase 4 Report Body and Synopsis Page: 3 of 81 Synopsis TITLE OF TRIAL A 24-week, multi-centre, controlled, open-labelled, parallel, randomised efficacy and safety comparison of biphasic insulin aspart 30 once

More information

These results are supplied for informational purposes only.

These results are supplied for informational purposes only. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information

SUPPLEMENTARY DATA. Supplementary Table 1. Baseline Patient Characteristics

SUPPLEMENTARY DATA. Supplementary Table 1. Baseline Patient Characteristics Supplementary Table 1. Baseline Patient Characteristics Normally distributed data are presented as mean (±SD), data that were not of a normal distribution are presented as median (ICR). The baseline characteristics

More information

Individual Study Table Referring to Item of the Submission: Volume: Page:

Individual Study Table Referring to Item of the Submission: Volume: Page: 2.0 Synopsis Name of Company: Abbott Laboratories Name of Study Drug: Meridia Name of Active Ingredient: Sibutramine hydrochloride monohydrate Individual Study Table Referring to Item of the Submission:

More information

SUPPLEMENTARY DATA. Supplementary Table S1. Clinical characteristics of the study subjects.*

SUPPLEMENTARY DATA. Supplementary Table S1. Clinical characteristics of the study subjects.* Supplementary Table S1. Clinical characteristics of the study subjects.* T2D ND n (F/M) 66 (21/45) 25 (7/18) Age (years) 61.8 ± 6.9 49.4 ± 7.3 # Body weight (kg) 95 ± 16 105 ± 13 # Body mass index (kg.

More information

The target blood pressure in patients with diabetes is <130 mm Hg

The target blood pressure in patients with diabetes is <130 mm Hg Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Rawshani Aidin, Rawshani Araz, Franzén S, et al. Risk factors,

More information

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Know Your Number Aggregate Report Single Analysis Compared to National Averages Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics

More information

Clinical Trial Synopsis TL-OPI-525, NCT#

Clinical Trial Synopsis TL-OPI-525, NCT# Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS

More information

Nature Medicine: doi: /nm.3891

Nature Medicine: doi: /nm.3891 Supplementary Figure 1. Subjective responses. Thermal sensation, thermal comfort and self-reported shivering, determined at several time points (from t = min until t = 36 min) after entering the cold room,

More information

ClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:

ClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company: These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov

More information

Sponsor: Sanofi Drug substance(s): Lantus /insulin glargine. Study Identifiers: U , NCT Study code: LANTUL07225

Sponsor: Sanofi Drug substance(s): Lantus /insulin glargine. Study Identifiers: U , NCT Study code: LANTUL07225 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):

More information

Page: 1 / 5 Produced by the Centre for Reviews and Dissemination Copyright 2018 University of York

Page: 1 / 5 Produced by the Centre for Reviews and Dissemination Copyright 2018 University of York Weight management using a meal replacement strategy: meta and pooling analysis from six studies Heymsfield S B, van Mierlo C A, van der Knaap H C, Heo M, Frier H I CRD summary The review assessed partial

More information

Standard Operating Procedure 11. Completion of DAFNE Data Collection: Full Post Course Form F04.010, Version 8

Standard Operating Procedure 11. Completion of DAFNE Data Collection: Full Post Course Form F04.010, Version 8 Standard Operating Procedure 11 Completion of DAFNE Data Collection: Full Post Course Form F04.010, Version 8 Date Version Issue Review Contact Approved Date Date Person October 2013 9 October 2013 March

More information

Substantial Decrease in Comorbidity 5 Years After Gastric Bypass

Substantial Decrease in Comorbidity 5 Years After Gastric Bypass Substantial Decrease in Comorbidity 5 Years After Gastric Bypass A Population-based Study From the Scandinavian Obesity Surgery Registry Sundbom, Magnus; Hedberg, Jakob; Marsk, Richard; Boman, Lars; Bylund,

More information

STATISTICAL ANALYSIS PLAN (SAP)

STATISTICAL ANALYSIS PLAN (SAP) STATISTICAL ANALYSIS PLAN (SAP) The effects of an intensive lifestyle treatment vs. conventional multi-factorial care on glycaemic control and anti-diabetic medications in patients with type 2 diabetes

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney

More information

Patients must have met all of the following inclusion criteria to be eligible for participation in this study.

Patients must have met all of the following inclusion criteria to be eligible for participation in this study. Supplementary Appendix S1: Detailed inclusion/exclusion criteria Patients must have met all of the following inclusion criteria to be eligible for participation in this study. Inclusion Criteria 1) Willing

More information

High intensity exercise improves cardiac structure and function and reduces liver fat in adults with Type 2 diabetes

High intensity exercise improves cardiac structure and function and reduces liver fat in adults with Type 2 diabetes High intensity exercise improves cardiac structure and function and reduces liver fat in adults with Type 2 diabetes Sophie Cassidy, s.cassidy@ncl.ac.uk 1) Concentric remodelling 1.2 * Eccentricity ratio

More information

HEALTH PROFESSIONAL v SANOFI

HEALTH PROFESSIONAL v SANOFI CASE AUTH/3062/8/18 HEALTH PROFESSIONAL v SANOFI Toujeo leaflet A consultant physician complained about a six-page A5 gate-folded leavepiece produced by Sanofi. The leavepiece related to Toujeo (insulin

More information

Comprehensive Screening Detects Undiagnosed Autoimmunity In Adult-onset Type 2 Diabetes

Comprehensive Screening Detects Undiagnosed Autoimmunity In Adult-onset Type 2 Diabetes Comprehensive Screening Detects Undiagnosed Autoimmunity In Adult-onset Type 2 Diabetes SRINIVASA R. NAGALLA, MD, PATURI V. RAO, MD, CARYN K. SNYDER, MPH, JERRY P. PALMER, MD, CHARLES T. ROBERTS, PhD DiabetOmics,

More information